Dr Garrido speaks with ecancer at the ASH 2017 annual meeting about results from 500 patients enrolled in a risk-adapted phase II trial of intensive chemotherapy followed or not by autologous or allogeneic HCT.
She outlines the cytogenetic and MRD classifications for high, intermediate and low-risk trial arms, and their improved survival endpoints based on risk stratification and subsequent treatment.
Dr Garrido hopes that further NGS validation will confirm markers for risk and response.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.